Many countries around the world that appeared to have kicked COVID-19 are reporting surges, largely the result of the so-called “stealth” Omicron variant, BA.2.
Shares of Adaptive Biotechnologies climbed on March 9 after the company announced a reorganization of priorities to spur future growth, including a workforce reduction of approximately 12 percent.
An experimental oral drug being developed by Redhill Biopharma Inc. interrupts a process that helps the coronavirus infect cells and might keep COVID-19 patients from becoming seriously ill, the company said. Additionally, the risk of hospitalization after vaccination with Johnson & Johnson’s COVID-19 vaccine was about five times higher than for those who received the Pfizer and BioNTech shot, a large French study found.
The U.S. health regulator approved a therapy developed by Johnson & Johnson and the healthcare company’s China-focused partner Legend Biotech Corp. to treat a type of white blood cell cancer.
U.S. Bankruptcy Court Judge Michael Kaplan ruled that Johnson & Johnson be allowed to continue with the company’s controversial spinoff strategy to settle with people who filed lawsuits claiming that J&J’s talc-based baby powder causes cancer.
The three largest U.S. drug distributors and drugmaker Johnson & Johnson agreed to finalize a proposed $26 billion settlement resolving claims by states and local governments that they helped fuel the U.S. opioid epidemic.
The success of vaccines against COVID-19 has become a cash cow for Moderna, the Pfizer and BioNTech team, and Johnson & Johnson. Moderna, Pfizer, and J&J earned combined revenue of $31 billion from their COVID-19 vaccines in 2021.
A Johnson & Johnson subsidiary proposed on February 18 that it would submit to an independent examination of the corporate restructuring the healthcare giant undertook in an attempt to settle in U.S. bankruptcy court thousands of lawsuits alleging that J&J baby powder and other talc products cause cancer.
RNA-focused Remix Therapeutics agreed on a strategic small-molecule discovery and development collaboration with Janssen Pharmaceutica N.V., a division of Johnson & Johnson.
EVERSANA, the pioneer of next generation commercial services to the global life sciences industry, and THREAD, a leading technology and service provider enabling electronic clinical outcome assessments (eCOAs) and decentralized clinical trials (DCTs), announced a new combined offering to give pharmaceutical companies a comprehensive and simultaneous view of clinical research participants, followed by data and detailed analysis across the care continuum.
